RXRX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

RXRX ▲ +10.41% at T+20d

NEUTRAL call ✓ call won +10.41% · α vs SPY +2.55% · entry $3.17 → $3.50

Next anchor: T+60d in 7d

Last close $3.15 (close Jun 12) · -0.63% from $3.17 entry

Entry anchored
Mar 24, 03:59 PM ET
via Databento tick

T+1d

-0.63%

call -0.63% · α +1.14%

$3.15

settled 3mo ago

T+5d

-3.47%

call -3.47% · α -3.23%

$3.06

settled 3mo ago

T+20d

+10.41%

call +10.41% · α +2.55%

$3.50

settled 8w ago

T+60d

—

call — · α —

—

in 7d

Price Chart

Loading chart...

Executive Summary

Recursion Pharmaceuticals announced the appointment of Dr. Vicki Goodman as its new Chief Medical Officer, effective April 6, 2026, replacing outgoing CMO Dr. David Mauro. The leadership change is part of a planned transition as the company advances its clinical pipeline, with no accompanying financial updates or material operational changes disclosed.

Actionable Insight

Monitor upcoming clinical trial updates and regulatory filings for signs of accelerated development pace under new CMO leadership. Assess whether pipeline progression improves relative to prior timelines.

Key Facts

Dr. Vicki Goodman will become Chief Medical Officer of Recursion effective April 6, 2026.
Dr. David Mauro is transitioning out of the CMO role after approximately three years.
No financial terms, compensation details, or material operational changes were disclosed.
The company reaffirmed it is on track with previously communicated clinical and regulatory expectations.
Dr. Goodman brings extensive oncology drug development experience from Mural Oncology, Exelixis, Merck, and Bristol Myers Squibb.

Financial Impact

Minimal near-term financial impact; no disclosed cost or revenue implications.

operating expensesR&D leadership

Risk Factors

Leadership transition could temporarily slow decision-making in clinical development.
High expectations for Dr. Goodman may create pressure if pipeline milestones are delayed.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3262112

9 reports for RXRX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for RXRX — sortable, filterable
	Type				Now
Jun 11, 2026 3d ago	Institutional Cluster NEUTRAL ★ 3/10	$3.10 awaiting T+5	awaiting T+5	—	$3.15 (+1.61%)
Jun 5, 2026 9d ago	Insider Cluster NEUTRAL ★ 2/10	$3.32 awaiting T+5	awaiting T+5	—	$3.15 (−4.98%)
May 29, 2026 16d ago	Press Release NEUTRAL ★ 2/10	$3.79 $3.32	▼ −12.53%	▼ −9.78%	$3.15 (−16.89%)
May 6, 2026 5w ago	Press Release MIXED ★ 6/10	$3.43 $3.15	▼ −8.16%	▼ −9.29%	$3.15 (−8.16%)
May 5, 2026 5w ago	Insider Cluster NEUTRAL ★ 2/10	$3.37 $3.26	▼ −3.26%	▼ −5.25%	$3.15 (−6.53%)
Apr 7, 2026 9w ago	Insider Cluster NEUTRAL ★ 3/10	$3.19 $3.54	▲ +10.97%	▲ +5.64%	$3.15 (−1.25%)
Mar 25, 2026 11w ago	Press Release NEUTRAL ★ 3/10	$3.17 $3.06	▼ −3.47%	▼ −3.23%	$3.15 (−0.63%)
Mar 17, 2026 12w ago	Insider Cluster NEUTRAL ★ 3/10	$3.42 $3.17	▼ −7.31%	▼ −4.66%	$3.15 (−7.89%)
Feb 25, 2026 15w ago	8-K BULLISH ★ 8/10	$3.77 $3.64	▼ −3.45%	▼ −2.35%	$3.15 (−16.45%)

US Market Status

Market Closed — Opens in 4h 7m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access